ReNeuron Group plc Notification of Interim Results (3245W)
13 November 2017 - 10:30PM
UK Regulatory
TIDMRENE
RNS Number : 3245W
ReNeuron Group plc
13 November 2017
13 November 2017 AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
Notification of Interim Results
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, intends to announce its
interim results for the six months ended 30 September 2017 on
Thursday 14 December 2017.
A meeting for analysts will be held at 9.30am on the morning of
14 December 2017 at the offices of Buchanan, 107 Cheapside, London
EC2V 6DN.
For a webcast of the analyst presentation, please log on to the
following web address approximately 10 minutes before 9.30am on the
day of the results:
http://vm.buchanan.uk.com/2017/reneuron141217/registration.htm
A recording of the presentation will be made available on
ReNeuron's website, www.reneuron.com.
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
N+1 Singer Advisory LLP +44 (0) 20 7496 3000
Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for motor disability as a result of stroke, for
critical limb ischaemia and for the blindness-causing disease,
retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOREAFFDFAAXFFF
(END) Dow Jones Newswires
November 13, 2017 06:30 ET (11:30 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024